---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-338006"
form_type: "8-K"
ticker: "DFTX"
cik: "0001813814"
company_name: "Definium Therapeutics, Inc."
filed_at: "2026-08-06T20:10:59+00:00"
generated_at: "2026-08-06T20:14:31.100518+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Definium Therapeutics Q2 net loss $159M; Phase 3 Emerge MDD study meets primary endpoint

## Summary
- Phase 3 Emerge in MDD met primary endpoint: 8.1-point MADRS improvement vs placebo at Week 6 (p<0.0001).
- Cash, equivalents and investments $1.1B as of June 30, 2026, up from $411.6M at Dec 31, 2025.
- Net loss $159.0M for Q2 2026 vs $42.7M in Q2 2025, including $86.2M non-cash warrant liability charge.
- R&D expenses $48.7M, G&A $26.4M; completed public offering of $805M gross proceeds.
- Topline GAD results from Voyage expected week of Aug 10; Panorama in Sept 2026.

## SEC filing metadata
- accession: 0001193125-26-338006
- form_type: 8-K
- ticker: DFTX
- cik: 0001813814
- company_name: Definium Therapeutics, Inc.
- filed_at: 2026-08-06T20:10:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1813814/000119312526338006/0001193125-26-338006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1813814/000119312526338006/dftx-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-338006
- JSON: https://secwatch.observer/filing/0001193125-26-338006.json
- Plain text: https://secwatch.observer/filing/0001193125-26-338006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.